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osting by EAbstract Photo-thermal therapy (PTT) is a minimally-invasive therapy in which photon energy is
converted into heat to kill cancer. Gold nanoparticles absorb light strongly and convert photon
energy into heat quickly and efﬁciently, thereby making them superior contrast agents for PTT.
This gold nanoparticle-assisted PTT called PPTT has showed great popularity and success in recent
years. The present review starts with the outline of optical properties that base PPTT followed by
description of the synthesis of several gold-based nanoparticles that have been used in PPTT includ-
ing gold nanospheres, gold nanoshells, gold nanorods and gold nanocages. Therapeutic outcomes
will be discussed for each type of gold nanoparticles. Cell death mechanisms and future perspectives
of PPTT will be brieﬂy mentioned at the end.
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Cancer is a disease characterized by uncontrolled growth and
spread of abnormal cells. It is caused by DNA damage which
can be inherited or induced by environmental factors. Cancer
can form tumors on tissues or grow in the body ﬂow system. In
the United States, cancer and heart attack compete in being
the number one killers of humans, with 1,479,350 new cases
of cancer and 562,340 deaths estimated in 2009.1
Current mainstream treatments include surgery, chemo-
therapy or radiation. Surgical extirpation is highly effective
in primary tumors, but it is limited to surgically recognizable
and accessible tumors and thus cancer cells may not be com-
pletely removed. Chemotherapy is the use of chemical drugs
to ﬁght cancer. The systemically administrated drugs circulate
in the body to kill cells that divide rapidly, especially cancer
cells. It commonly has signiﬁcant side effects due to the drug
toxicity to normal cells and is subject to the development of
resistance by the cancer cells. Radiation, the use of high energy
ionization particles (X-rays, gamma rays or electrons) to dam-
age cell and tissue at a molecular level, is often used as a com-
plementary approach, to eradicate remaining cancer cells after
surgery. It can cause damage to the healthy tissues close to the
cancer cells or in the path of the radiation beam.
Photo-thermal therapy (PTT), a minimally-invasive thera-
peutic strategy in which photon energy is converted into heat
sufﬁcient to destroy cancer cells, has been used to treat cancer
to some degree in the past few decades.2 Heating sources
including near infrared or visible light, radiofrequency waves,
microwaves, and ultrasound waves are used to induce moder-
ate temperature rise in a speciﬁc target region to destroy the
cancer cells, clinically termed as hyperthermia. Due to low
absorption efﬁciency of the natural tissue absorbents, synthetic
organic dye molecules, such as indocyanine green, naphthalo-
cyanines and porphyrins coordinated with transition metals
are externally administrated into the tumor sites to enhance
the photothermal effects. As the dye molecules photobleach
quickly, PTT has not been widely used in clinical settings.
Recently PTT has attracted new interest in the battle
against cancer because of the generation of a novel class of
photothermally sensitized agents – nanoscale gold. Gold metal
at the nano-scale (billionths of a meter) shows superior lightabsorption efﬁciency over conventional dye molecules. Upon
irradiation to electromagnetic radiation, strong surface ﬁelds
are induced due to the coherent excitation of the electrons in
the nanogold. The rapid relaxation of these excited electrons
produces strong localized heat capable of destroying surrounding
targeted cancer cells via hyperthermia or other thermal-based
effects. This photothermal therapy induced by plasmonic
gold nanoparticles is called plasmonic photothermal therapy
(PPTT).3 In this chapter, we will give an overview of the gold
nanotechnology-driven photothermal cancer therapy including
a discussion of the optical properties, synthesis, therapeutic
outcomes and insights into cell death mechanisms.
2. Optical properties of gold nanoparticles
2.1. Localized surface plasmon resonance
Compared to non-metal nanoparticles, plasmonic nanoparti-
cles hold a unique photophysical phenomenon, called localized
surface plasmon resonance (LSPR) (Fig. 1A).4 This LSPR is
the result of the interaction of nanoparticles with light of res-
onant frequency. As a result of the absorption of resonant
light, the free electrons of the metal exhibit a collective coher-
ent oscillation around the nanoparticle surface. This coherent
oscillation induced as a result of the absorption of light in res-
onance with the incident light is called the localized surface
plasmon resonance. This plasmon resonance leads to a strong
extinction band around 520 nm in the visible spectral region,
which is the reason for the brilliant red color of the nanogold
solution. Back in 1908 Gustav Mie5 theoretically explained this
phenomenon by solving Maxwell equations. For nanoparticles
much smaller than the wavelength of the light (25 nm), the
dipole oscillation is dominant and the extinction cross section
is simpliﬁed to the following well known expression (Eq. (1)).
Cext ¼ 24p
2R2e3=2m
k
ei
ðer þ 2emÞ2 þ e2i
ð1Þ
where Cext is the extinction cross section, R is the radius of the
particle, k is the wavelength of the incident light, em is the
dielectric constant of the surrounding medium, e is the com-
plex dielectric constant of the metal given by e=
Figure 1 Schematic illustration of localized surface plasmon resonance (A) and calculated absorption and scattering properties of gold
nanoparticles in different sizes (B). The electric ﬁeld of incident light induces coherent collective oscillation of conduction band electrons
with respect to the positively charged metallic core. This dipolar oscillation is resonant with the incoming light at a speciﬁc frequency that
depends on particle size and shape. The absorption and scattering efﬁciencies depend on the size of the nanoparticles. Increasing
nanoparticle size leads to an increase of light scattering contribution. (A) Reproduced with permission from Huang et al.4; (B) reproduced
with permission from Jain et al.6
Plasmonic photo-thermal therapy (PPTT) 3er(x) + iei(x). The real part of the dielectric constant of the
metal determines the SPR position and the imaginary part
determines the bandwidth. The SPR resonance occurs when
er(x) = 2em. For larger nanoparticles, full Mie theory has
to be used to explain the LSPR considering all multiple elec-
tron oscillations.
The LSPR is dependent on factors affecting the electron
charge density on the particle surface, such as the particle size,
shape, structure, and the dielectric properties of the metal and
the surrounding medium. Spherical gold, silver, and copper
nanoparticles have strong SPR band in the visible region, while
other metals show broad and weak bands in the UV region.
Hollow or core-shell structures show a very red shifted band
of the LSPR wavelength compared to the solid structures.
Anisotropic nanoparticles, such as rods, triangles, and
branched structures also exhibit a red shifted SPR band com-
pared to their spherical analogs.
2.2. Optical absorption and scattering
The total loss of light interacting with plasmonic nanoparti-
cles, i.e., the extinction, is a sum of absorption and scattering.
Light absorption results when the photon energy is dissipated
due to inelastic processes. Light scattering occurs when the
photon energy causes electron oscillations in the matter which
emit photons in the form of scattered light at the same fre-
quency as the incident light. The contribution of these two
parts to the total extinction can be calculated by using Mie the-
ory or discrete dipole approximation (DDA). Fig. 1B shows
calculated absorption, scattering and extinction efﬁciencies of
gold nanoparticles in different sizes by using the full Mie the-ory.6 For small nanoparticles, the extinction is dominated by
absorption. Increasing nanoparticle size signiﬁcantly increases
light scattering.
In noble metal nanoparticles, both the absorption and scat-
tering efﬁciencies are strongly enhanced due to the LSPR. The
light absorption or scattering of gold nanoparticles is at least
1000 times stronger than the absorption or emission of any or-
ganic dye molecules. This makes gold nanoparticles very
promising in a wide range of applications including sensing,
imaging and photo-thermal therapy.
2.3. Tuning LSPR to NIR region
By changing the structure and shape, the LSPR frequency of
gold nanoparticles can be tuned to near infrared (NIR) region,
where light penetration in tissue is optimal. For this reason,
NIR-absorbing gold-based nanoparticles have received consid-
erable attention in PPTT.
Currently there are three major types of NIR-absorbing
gold-based nanoparticles that are useful in PPTT (Fig. 2):
gold nanoshell (Au NS),7 gold nanorod (Au NRs)4 and gold
nanocage (Au NCs).8 Au NS is composed of a spherical silica
core (100–200 nm in diameter) and a thin layer of gold (5–
20 nm). Its NIR absorption is ﬁrstly predicted by Neeves
and Birnboim in 19899 and then experimentally validated
by Halas and co-workers in 1998.10 This two concentric
spherical structures shows red-shifted absorption due to the
coupling between the inner and outer shell surface
plasmons.11 Decreasing the ratio of shell thickness to core ra-
dius largely red shifts the LSPR wavelength from the visible
to NIR region. As shown in Fig. 2, the LSPR wavelength
Figure 2 NIR-absorbing Au NPs in PPTT of cancer. Left column: Au NSs. Reproduced with permission from Loo et al.7; Middle
column: Au NRs. Reproduced with permission from Huang et al.4; Right column: Au NCs. Reproduced with permission from Hu et al.8;
First row: schematic illustration of the structures of Au NSs, NRs and NCs; Second row: TEM images; Third row: surface plasmon
extinction spectra. The surface plasmon band is tuned to the NIR region by changing the shell to core ratio, the aspect ratio and the
particle size, wall thickness and wall porosity for Au NSs, NRs and NCs, respectively.
4 X. Huang, M.A. El-Sayedshifts from 700 to 1000 nm when the shell thickness decreases
from 20 to 5 nm. The LSPR frequency decreases near-expo-
nentially with decrease in the shell thickness-to-core radius
ratio, with a trend that is universal and independent of the
nanoshell size, core material, shell metal, or surrounding
medium.12
Developed by Wang,13 Murphy14 and El-Sayed15 groups,
Au NR has gained considerable popularity in various applica-
tions due to their precisely and readily controlled NIR optical
properties. The cylinder shaped Au NR shows two absorption
bands: a strong absorption band in the NIR region due to the
electron oscillation along the longitudinal direction and a weak
band in the visible region around 520 nm due to electron oscil-
lation along the transverse direction. This optical behavior has
been well explained using Gans theory.16 The transverse band
is insensitive to the aspect ratio (length/width) of the rod. The
longitudinal band wavelength greatly red shifts from visible to
NIR region in a linear relationship with increased intensity
when the aspect ratio increases.17 The LSPR wavelength is
red shifted from 640 to 1050 nm by simply changing the aspect
ratio from 2.4 to 6.6 (Fig. 2). Compared to nanoshells, DDAcalculation shows that nanorods show 2–3 times stronger
absorption efﬁciency.8 Their physical dimension is also much
smaller than the nanoshells.
Compared to Au NS and NR, Au NC is developed as a
NIR-absorbing gold nanostructure by Xia group.18 It is com-
posed of a thin and porous gold wall with hollow interior.
Changing the wall thickness, the hole size and porosity can
tune the LSPR wavelength from the visible to the NIR region.
This is experimentally controlled by the amount of auric acid
that galvanically replaces silver cubes to obtain the nanocag-
es.18 Increasing the amount of the auric acid red shifts the
LSPR (Fig 2). DDA calculation shows a 2 nm decreasing of
the wall thickness cause a red shift of the LSPR wavelength
by about 100 nm.19 Increasing the polarity does not inﬂuence
the position of the LSPR band, but signiﬁcantly decreases
the intensity in a linear way.
2.4. Photo-thermal properties
The PPTT rationale is that plasmonic nanoparticles have use-
ful non-radiative photo-thermal properties. The absorbed
Plasmonic photo-thermal therapy (PPTT) 5light is converted into heat through a series of photo-physical
processes.20 Firstly, the absorbed light is quickly converted to
heat to form a hot metallic lattice by two processes: electron-
electron relaxation occurring on femto-seconds and electron-
phonon relaxation occurring on the picoseconds. Hot electron
temperatures of several thousand degree kelvin are easily
reached in the nanoparticles even with laser excitation powers
as low as 100 nJ and the lattice temperature on the order of a
few tens of degrees can be achieved. The lattice then cools off
by phonon–phonon relaxation. It means the heat is dissi-
pated from the particles into the surrounding environment
to heat up the species surrounding the nanoparticles. When
the nanoparticles are attached to cancer cells, the heat can
change the function of the cells and even destroy them
depending on the amount of heat generated by the hot
nanoparticles.
Such fast energy conversion and dissipation can be readily
used for the heating of the local environment by using light
radiation with a frequency strongly overlapping with the
nanoparticle SPR absorption band. For sufﬁcient heating,
relatively modest continuous laser light is generally used.
Depending on the LSPR wavelength, the laser light is either
in the visible region using spherical gold nanoparticles or in
the near infrared (NIR) region using NIR-absorbing gold-
based nanoparticles. For in vivo applications, NIR PPTT is
favorable as the NIR light penetrates tissue optimally due
to minimal absorption by the major absorbents of water
and hemoglobin in the tissue. Thus Au NSs, NRs, and
NCs have been actively investigated for their potentials in
PPTT of cancer.3. Nanoparticle synthesis
3.1. Gold nanospheres
Modern synthesis of visible-absorbing gold nanoparticles
dates back to 1857 when Faraday made the colloid gold by
reducing auric acid with phosphors.21 Current popular meth-
od for making colloid gold was developed by Turkevich
et al. in 195122 and later modiﬁed by Frens in 1973,23 named
as citrate reduction method. In this method, sodium citrate re-
duces auric acid at 100 C to form nanoparticles. The nega-
tively charged citrate also binds to the nanoparticles and
stabilizes them in the solution phase. Changing the amount
of sodium citrate makes nanoparticles of different sizes from
a few to over a hundred nanometers. Some other methods in-
clude Schmid method,24 Brust–Schiffrin method25 and seed-
mediated growth method.26
3.2. Gold nanoshells
Au NSs were developed by Halas group in 1997.10 Silica
nanoparticles around 120 nm in diameter are ﬁrstly prepared
by Sto¨ber method in which tetraethyl orthosilicate is reduced
by ammonium hydroxide. The nanoparticles are laminated
with amino-propyltriethoxysilane and then coated with small
gold nanoparticles by covalent interaction. A uniform shell
of gold is formed by depositing more gold onto the gold
seed layer in the presence of auric acid and reducing agent
of sodium borate. The concentration of auric acid deter-
mines the shell thickness. It is noticed that precise control-ling of the metallic shell thickness, coverage and
smoothness is challenged because of the instability of gold
cluster and the difﬁculty of deposition of metal atoms onto
the silica core. Nonetheless, this method is regarded as the
general way to synthesize dielectric metal nanoshell
structures.
3.3. Gold nanorods
High yields of gold nanorods suspension were ﬁrstly prepared
by the electrochemical method developed by Wang and co-
workers in 1990s.13 A gold metal plate anode, a platinum plate
cathode and a silver plate are immersed in an electrolytic solu-
tion consisting of a rod inducing CTAB surfactant and a co-
surfactant TOAB (tetradodecylammonium bromide). The gold
metal is electrolyzed to generate gold ions which then migrate
to the cathode where they are reduced to gold atoms to form
nanorods. The aspect ratio of the nanorods is controlled by
the concentration and the release rate of silver ions produced
from the redox reaction between gold ion and silver plate. La-
ter, a seed mediated growth method was developed by Murphy
group14 and later modiﬁed by El-Sayed group.15 This method
has turned out to be the most popular method for making col-
loidal gold nanorods on account of their simplicity of the pro-
cedure, high quality and yield of nanorods, ease of particle size
controlling and ﬂexibility for structural modiﬁcations. This
method involves two steps: In the ﬁrst step, 2–5 nm gold nan-
ospheres are prepared as seed NPs by the reduction of auric
acid with sodium borate. In the second step, a bulk gold solu-
tion in the presence of CTAB surfactant and silver ions is re-
duced to Au+1 solution by ascorbic acid. To this growth
solution, the seed NPs are introduced and NRs are formed
within 2 h by anisotropic growth from the sphere NPs. The
nanorods are capped by the CTAB molecules in a bilayer
structure. The aspect ratio is controlled by the amount of silver
ions with increasing amount of silver for higher aspect ratios.
The use of a co-surfactant BDAC (benzyldimethylhexadecy-
lammonium) facilitates the growth of nanorods of higher as-
pect ratios.
One other method for making monodisperse Au NRs is the
earlier reported hard template method,27 in which nanorods
are grown in a nanoporous solid template and then dispersed
in an aqueous or organic solvent to form nanorods solution.
Photochemical reduction,28 X-ray irradiation,29 proton beam
irradiation,30 microwave reduction31 and solvothermal reduc-
tion32can also make nanorods with good quality.
3.4. Gold nanocages
Au NCs are generally synthesized by a galvanic replacement
reaction developed by Xia group in 2002.18 Typically, silver
nanocubes are prepared as a template by reducing silver nitrate
with polyvinyl pyrolidone (PVP) at an elevated temperature.
PVP also serves as capping agents and the reaction solvent.
The size of the silver nanocubes is controlled by the amount
of silver nitrate, with increased amount of silver ions for nano-
cages of larger sizes. To the puriﬁed silver nanocube solution,
hydrogen tetrachloroaurate was injected at the boiling temper-
ature. The auric acid is reduced to gold atoms by the silver
nanoparticles due to higher standard reduction potential of
gold than silver. The gold atoms epitaxially nucleate on the sil-
ver nanocube and then grow into a thin shell around the silver
6 X. Huang, M.A. El-Sayedtemplate. The fact that it takes three silver atoms to reduce one
gold atom creates the hole in the cubes as the wall of the empty
cube becomes gold leading to a hollow structure having gold
walls. With holes in them the wall thickness and the size of
holes of the Au NCs are controlled by the amount of gold salt.
Increasing the amount of gold salt produces nanocages with
thinner shells and porous walls.4. Therapeutic applications
4.1. Gold nanospheres
PPTT involving contrast agents of gold-based nanoparticles
was reported for the ﬁrst time by Lin and co-workers in
2003 using gold nanospheres in combination with a nanosec-
ond visible pulsed laser.33 Anti-CD8 immunogold nanoparti-
cles speciﬁcally bound to T lymphocyte cells and subsequent
irradiation with laser pulses lead to destruction of over 90%.
Of the cells, visible PPTT of cancer cells using gold nanoparti-
cles and pulsed laser has been extensively investigated later by
Zharov et al.34 It was found that cell death could be induced by
a single nanosecond pulse at an energy of 2–3 J/cm2 with 10–15
gold nanoparticles per cell. Visible PPTT of cancer cells using
gold nanoparticles was later been studied by El-Sayed group
using a continuous argon ion laser.35 By using a numerical
model, the group found that a temperature around 75 C
was reached in the cells for cell death by the laser heating of
gold nanoparticles on the cells.36 Visible PPTT can be used
for fundamental in vitro studies, but its practical applications
in in vivo are limited as visible light does not penetrate tissue
optimally. For in vivo and clinical therapy of tumors under
skin and deeply seated within tissue, NIR light is required be-
cause of its deep penetration due to minimal absorption of the
hemoglobin and water molecules in tissues in this spectral re-
gion. Thus, NIR-absorbing plasmonic nanoparticles are fa-
vored in PPTT of cancer.
4.2. Gold nanoshells
NIR PPTT of cancer using gold-based nanoparticles was
ﬁrstly developed by Halas and co-workers using Au NSs in
2003.37 Au NSs were prepared and stabilized with poly (ethyl-Figure 3 NIR PPTT using Au NSs. (A) In vitro PPTT; (B) in vi
treatment; Dark: untreated controls. While laser itself does not affect t
the laser irradiation area at a laser intensity of 37 W/cm2. Tumors are
shame and control groups. (A) Reproduced with permission from Hirene) glycol (PEG). In the presence of PEG-coated Au NSs,
breast cancer cells were destroyed after exposure to cw NIR
light at an intensity of 35 w/cm2 for 7 min (Fig. 3A). Using a
mouse model, they demonstrated that breast cancer xeno-
grafted tumors were destroyed after Au NSs intratumoral
injection and NIR laser irradiation for a few minutes
(Fig. 3B). MRI showed a temperature rise of 37 C. Subse-
quent studies showed complete tumor eradication at 10 days
post-treatment.38 They also showed that 55% of the mice
receiving NS therapy/laser treatment experienced complete tu-
mor regression without regrowth after 90 days.39 The NSs ex-
hibit a blood half-life time about 4 h and are dominantly
accumulated in mouse liver and spleen. They also found that
the nanoparticles started to clear out of body after 6 months.
Their other research on NIR PPTT using Au NSs can be found
in their recent review.40
4.3. Gold nanorods
NIR PPTT using gold nanorods was ﬁrstly demonstrated by
El-Sayed group in 2006 through in vitro studies.41 The NRs
are functionalized with anti-EGFR antibodies for speciﬁc
binding to EGFR-positive human oral cancer cells. After
exposure to a beam of focused NIR light, the cancer cells were
destroyed without affecting the normal cells (Fig. 4A and B).
The method has also been demonstrated on some other cell
types by other researchers.42,43 Two years later, the group
demonstrated the feasibility of PEGylated Au NRs for tumor
photothermal ablation using a human oral cancer xenograft
mouse model.44 NIR imaging located the tumors due to the
light absorption of the NRs that were treated either intrave-
nously or intratumorally (Fig. 4C). Tumor growth was signif-
icantly inhibited (p< 0.05) after exposure to a low dose of
NIR light (1–2 W/cm2, 10–15 min) for the NR-treated groups
(Fig. 4D). Thermal transient measurements showed that the
temperature increased by over 20 is sufﬁcient to induce tumor
tissue destruction. Very recently, Bhatia and co-workers
showed that single intravenous injection of PEGylated Au
NRs enables complete eradication of all irradiated tumors in
mice without regrowth over 50 days.45 They also conducted a
quantitative comparison of the photothermal effects between
Au NSs and NRs. Their results show that NRs generate heat
over six times faster than NSs per gram of gold. They have avo tumor PPTT. Blank: NSs and laser treatment; Gray: shame
he cell viability, the treatment of Au NSs induces cell death within
completely ablated for the NSs and laser treated groups, but not
sch et al.37; (B) reproduced with permission from O’Neal et al.38
Figure 4 NIR PPTT using Au NRs. (A and B) Selective in vitro photothermal cancer therapy; (C and D) in vivo NIR tumor imaging
and PPTT therapy. At 10 W/cm2, the cancer cells within the laser spot undergo irreversible photodestruction (A) while the normal cells are
not affected (B). The tumors are identiﬁed by a black spot under NIR illumination due to the light absorption by the nanorods that are
administrated into the tumor either intratumorally or intravenously. NIR irradiation of the nanorod treated tumors leads to signiﬁcant
inhibition of the tumor growth rate compared to control tumors. (A and B) Reproduced with permission from Huang et al.41; (C and D)
reprinted with permission from Dickerson et al.44
Plasmonic photo-thermal therapy (PPTT) 7blood half life time around 17 h, which is superior long com-
pared to Au NSs.
4.4. Gold nanocages
In 2007, Xia and co-workers demonstrated the feasibility of
Au NCs for NIR PPTT in vitro (Fig. 5A and B).46 The NCs
ere conjugated with anti-HER2 antibodies to target HER2
on breast cancer cells. Cell destruction was observed at a laser
power density of 1.5–4.7 W/cm2. They also found that the cell
circulation damage area is linearly dependent on the laser
power density. The cell death efﬁciency increases with increas-
ing laser exposure time until steady state at 5 min.47 The
in vivo nanoparticle active targeting and biodistribution of
Au NCs have been considerably studied by Li and co-work-
ers48 using anti-EGFR conjugated Au NCs and 111. In-label-
ing, they show that the NCs reach tumor at 6.8% ID/g.
Targeted PPTT of melanoma xenografted tumors on mice
was studied by the same group using the ligand of a-melano-cyte-stimulating hormone (MSH) analog that target melano-
cortin type-1receptor overexpressed in melanoma.49 The
tumor afﬁnity of targeted NCs is about three times of that
of the non-targeted ones. Photothermal studies show that tu-
mor uptake of [18F] ﬂuorodeoxyglucose, indicating reduced
metabolic activity after laser treatment. In contrast, there are
no signiﬁcant changes on the metabolic activity of tumors
for non-targeted and saline ones. Histologic examination also
shows that 66% of tumor tissues show necrotic response for
targeted NCs but only 7.9% were observed for the tumors
treated with the non-targeted NCs and saline solution
(Fig. 5C). These quantitative studies are very important on
the evaluation of PPTT outcomes.
5. Cell death mechanisms
Photothermally induced cell death can take place via apoptosis
or necrosis depending on the laser dosage, type and irradiation
time. It also depends on the subcellular location of the
Figure 5 NIR PPTT using Au NCs. (A and B) In vitro PPTT; (C) in vivo tumor tissue destruction assessed by histologic staining. Only
for the active targeted and laser treated tumors, tumor cells show extensive pyknosis (arrows), karyolysis (arrowheads), cytoplasmic
acidophilia, and degradation of the extracellular matrix of the tumor (asterisks). (A and B) Reproduced with permission from Chen
et al.46; (C) reproduced with permission from Lu et al.49
8 X. Huang, M.A. El-Sayednanoparticles. Cell death mechanisms have been explored to
some degree. Under pulsed laser irradiation studied by Zharov
and co-workers,50 laser pulses could induce cell damage via a
series of photothermal and accompanied phenomena; denatur-
ation or breakdown of proteins, cell cavitation, cellular struc-
ture rupturing, evaporation of cellular liquid and bubble
formation by shock waves due to particle thermal expansion,
evaporation, optical breakdown or plasma generation of Au
NPs. The photothermolysis mechanism of NIR PPTT with
cw lasers and Au NRs has been elucidated in some degree
by Wei and Cheng groups.43 Their studies show that the laser
energy used to destroy the cells when the nanoparticles are lo-
cated on the cytoplasm membrane is 10 times lower than that
required when the nanoparticles are internalized inside the
cytoplasm. The energy required for a fs laser is 10 fold lower
than that when a cw laser is used. Based on these results and
staining of cell membrane integrity, cell viability and actin ﬁl-
aments, they found that cell death was initiated by the disrup-
tion of the plasma membrane. Subsequent inﬂux of calcium
ions induces membrane blebbing and damage of actin ﬁla-ments. Obviously, apoptosis is the route of cell destruction
by the laser heating of gold nanoparticles.
6. Future perpective
As nanotechnologists, we have devised methods to destroy
cancer cells and thus stop cancer as a disease. In order to
use a new medicine, we must make sure that it does not have
side harmful effects. In most new medicines, this can take a
long time. If the harmful effects can be eliminated using animal
trials, the new medicine can be approved for human trials and
if it works safely in humans, the new medicine can be ap-
proved. This is where the use of gold nanotechnology is at
the moment. A great amount of detailed animal experiments
are now going on at the Egyptian National Research Center
and in the USA between the Winship Cancer of Emory Uni-
versity and our Nano-Technology group at Georgia Institute
of Technology aimed at determining and trying to solve the
toxicity of gold nanoparticles when injected in animals. If this
can be accomplished, we hope to go for human trials. This will
Plasmonic photo-thermal therapy (PPTT) 9take a long time that cannot be predicted as it depends on the
results of a great deal of research.References
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